PMID- 33851078
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210416
IS  - 2536-4553 (Electronic)
IS  - 2148-4902 (Print)
IS  - 2536-4553 (Linking)
VI  - 8
IP  - 2
DP  - 2021
TI  - The evaluation of dupilumab treatment response in atopic dermatitis patients.
PG  - 145-149
LID - 10.14744/nci.2020.42375 [doi]
AB  - OBJECTIVE: This study aims to demonstrate real-life effectiveness of dupilumab 
      treatment in moderate-to-severe atopic dermatitis patients. METHODS: The 14 
      patients diagnosed with moderate-to-severe atopic dermatitis were included in 
      this study. All of the patients started dupilumab treatment in our faculty 
      between October 2019 and October 2020. The patients were evaluated at the 
      beginning of the treatment and after 12 weeks of treatments. The baseline scoring 
      atopic dermatitis (SCORAD) scores, the total immunoglobulin E (IgE) levels, and 
      the visual analog scale (VAS) of 0-10 points for itch intensity compared with the 
      post-treatment scores. RESULTS: The SCORAD scores, the serum total IgE levels, 
      and the VAS itch scores of the patients receiving dupilumab treatment dropped 
      significantly following 12 weeks of dupilumab treatment. No significant 
      correlation was demonstrated between the initial SCORAD scores and the serum 
      total IgE values. Besides, no correlation was shown to exist in the reduction of 
      the SCORAD and the serum total IgE values after dupilumab treatment. CONCLUSION: 
      Dupilumab treatment showed significant improvement in disease severity with 
      remarkable reduction in serum total IgE levels.
CI  - Copyright: (c) 2021 by Istanbul Northern Anatolian Association of Public Hospitals.
FAU - Askin, Ozge
AU  - Askin O
AD  - Department of Dermatology, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of 
      Medicine, Istanbul, Turkey.
FAU - Yucesoy, Sera Nur
AU  - Yucesoy SN
AD  - Department of Dermatology, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of 
      Medicine, Istanbul, Turkey.
FAU - Serdaroglu, Server
AU  - Serdaroglu S
AD  - Department of Dermatology, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of 
      Medicine, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - Turkey
TA  - North Clin Istanb
JT  - Northern clinics of Istanbul
JID - 101684520
PMC - PMC8039099
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - dupilumab
OT  - scoring atopic dermatitis
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2021/04/15 06:00
MHDA- 2021/04/15 06:01
PMCR- 2020/11/25
CRDT- 2021/04/14 06:37
PHST- 2020/05/23 00:00 [received]
PHST- 2020/11/08 00:00 [accepted]
PHST- 2021/04/14 06:37 [entrez]
PHST- 2021/04/15 06:00 [pubmed]
PHST- 2021/04/15 06:01 [medline]
PHST- 2020/11/25 00:00 [pmc-release]
AID - NCI-8-145 [pii]
AID - 10.14744/nci.2020.42375 [doi]
PST - epublish
SO  - North Clin Istanb. 2020 Nov 25;8(2):145-149. doi: 10.14744/nci.2020.42375. 
      eCollection 2021.